Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing-Reference-Cited by-同舟云学术

Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing

Published:2018-07 Issue:4 Volume:32 Page:289-299
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Medeiros Bruno C.,Possick Jennifer,Fradley Michael

Funder

Pfizer Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference101 articles.

1. Translation of the Philadelphia chromosome into therapy for CML;Druker;Blood,2008

2. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome;Daley;Science,1990

3. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009;Chen;Leuk Lymphoma,2013

4. Clinical practice guidelines in oncology (NCCN guidelines);NCCN,2016

5. Treatment recommendations for chronic myeloid leukemia;Baccarani;Mediterr J Hematol Infect Dis,2014

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling;Molecular and Cellular Biochemistry;2024-07-15

2. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-05

3. Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity;Circulation Research;2024-03

4. Tyrosine Kinase Inhibitor-associated Cerebral Arterial Occlusive Disease Treated with High-flow Bypass Surgery: A Case Report;NMC Case Report Journal;2023-12-31

5. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors;PLOS ONE;2023-11-20